{"id":19275,"date":"2024-09-27T12:18:32","date_gmt":"2024-09-27T12:18:32","guid":{"rendered":"https:\/\/www.oxypharm.net\/?p=19275"},"modified":"2025-02-06T09:38:46","modified_gmt":"2025-02-06T09:38:46","slug":"sanivap-and-nocotech-an-effective-process-for-preventing-mrb-and-ehrb-2","status":"publish","type":"post","link":"https:\/\/www.oxypharm.net\/en\/sanivap-and-nocotech-an-effective-process-for-preventing-mrb-and-ehrb-2\/","title":{"rendered":"Sanivap and Nocotech: An Effective Process for Preventing MRB and EHRB"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]Infections caused by multidrug-resistant bacteria (MRB) and emerging highly resistant bacteria (eHRB) represent a major risk that can lead to therapeutic stalemate. Preventing healthcare-associated infections (HAIs) caused by these bacteria in healthcare facilities is therefore a major priority. Discover how using the process developed by Oxy\u2019Pharm combining Sanivap and Nocotech can help healthcare facilities prevent the build-up and spread of MRB and eHRB infections.<\/strong>[\/vc_column_text][vc_single_image image=”19023″ img_size=”full” css=””][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]MRB and eHRB Pose a Risk of Therapeutic Stalemate<\/strong>[\/vc_column_text][vc_column_text css=””]Infections caused by multidrug-resistant bacteria (MRB) and emerging highly resistant bacteria (eHRB) are growing at an alarming rate: +35% in 2023 within the AP-HP hospital system. In France, 12,500 people die each year from antibiotic-resistant infections.<\/p>\n

\u201cHospitals have seen massive antibiotic use over many years. Bacteria have developed strategies to evade and defend themselves against these antibiotics,\u201d says Mathieu Agnet, Scientific Director at Oxy\u2019Pharm.<\/p>\n

This situation is particularly worrying as infected patients become increasingly difficult to treat as a result, especially as certain bacterial strains are developing resistance to increasing numbers of antibiotics. In some cases, this can even lead to therapeutic stalemate, leaving the patient with no other effective treatment options.[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]MRB and eHRB: A Major Issue in Burn Units<\/strong>[\/vc_column_text][vc_column_text css=””]THE MOST FEARED MULTIDRUG-RESISTANT AND HIGHLY RESISTANT BACTERIA IN BURN CARE UNITS<\/strong>[\/vc_column_text][vc_column_text css=””]Emerging Highly Resistant Bacteria (eHRB) are commensal bacteria of the digestive tract and are resistant to many antibiotics. Within this category, Vancomycin-resistant Enterococci (VRE) and Carbapenemase-producing Enterobacteriaceae (CPE) are the most feared bacteria in burn care units.<\/p>\n

Multidrug-Resistant Bacteria (MRB) are bacteria that have multiple resistance mechanisms against several families of antibiotics. Methicillin-resistant Staphylococcus aureus (MRSA) and Imipenem-resistant Acinetobacter baumannii (ABRI) pose significant problems, particularly in burn units. ABRI, a particularly dangerous bacterium for immunocompromised individuals, is frequently found in burn units.[\/vc_column_text][vc_single_image image=”19042″ css=””][vc_empty_space][vc_column_text css=””]BURN PATIENTS ARE PARTICULARLY VULNERABLE<\/strong>[\/vc_column_text][vc_column_text css=””]Burn patients are at increased risk of colonization and infection by MRB and eHRB for two reasons. Firstly, burn patients\u2019 skin no longer acts as a protective barrier, facilitating bacterial entry into the body. Secondly, these patients are immunocompromised; their weakened immune system therefore provides a favorable environment for the rapid development of these bacteria[\/vc_column_text][vc_empty_space][vc_column_text css=””]MODES OF TRANSMISSION AND SPREAD OF PROBLEMATIC PATHOGENS<\/strong>[\/vc_column_text][vc_column_text css=””]eHRB often live in sink and shower drains. Meanwhile, ABRI thrives on inert surfaces. Since the bacterial reservoir is usually human, ABRI is brought in either by the patient themselves or by the healthcare team. Transmission occurs directly from patient to caregiver or caregiver to patient, and indirectly through contaminated hands, equipment, furniture, and medical devices. The twofold problem posed by ABRI is its ability to survive on inert surfaces and its extreme resistance to many types of antibiotics. \u201cIt is therefore very difficult to eradicate, especially as it is difficult to identify the infectious source maintaining the infection on the ward or in the patient\u2019s room,\u201d says Mathieu Agnet.[\/vc_column_text][vc_empty_space][vc_column_text css=””]Measures to Control the Spread of MRB and eHRB<\/strong>[\/vc_column_text][vc_column_text css=””]Preventing bacterial infections relies on respecting hospital hygiene rules. There are three levels of precautions:<\/p>\n

 <\/p>\n